Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 543 results
Filters: Keyword is Humans  [Clear All Filters]
Found 543 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

A

Sax PE, Tierney C, Collier AC, et al. "Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results." J. Infect. Dis.. 2011;204(8):1191-201.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Valcour V, Yeh T-M, Bartt R, et al. "Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection." HIV Med.. 2009;10(2):103-10.
L Wheat J, Connolly P, Smedema M, et al. "Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole." J. Antimicrob. Chemother.. 2006;57(6):1235-9.
Pond SLKosakovs, Frost SDW, Grossman Z, Gravenor MB, Richman DD, Brown AJLeigh. "Adaptation to different human populations by HIV-1 revealed by codon-based analyses." PLoS Comput. Biol.. 2006;2(6):e62.
John M, Heckerman D, James I, et al. "Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs." J. Immunol.. 2010;184(8):4368-77.
Amorosa VK, Luetkemeyer A, Kang M, et al. "Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial." HIV Clin Trials. 2013;14(6):274-83.
Canter JA, Robbins GK, Selph D, et al. "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy." J. Infect. Dis.. 2010;201(11):1703-7.
Crawford KW, Spritzler J, Kalayjian RC, et al. "Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir." AIDS Res. Hum. Retroviruses. 2010;26(6):635-43.
Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.
Smurzynski M, Collier AC, Koletar SL, et al. "AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics." HIV Clin Trials. 2008;9(4):269-82.
McComsey GA, Kendall MA, Tebas P, et al. "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV." AIDS. 2007;21(18):2473-82.
Stüve O, Marra CM, Bar-Or A, et al. "Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis." Arch. Neurol.. 2006;63(10):1383-7.
McCausland MR, Juchnowski SM, Zidar DA, et al. "Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy." PLoS ONE. 2015;10(10):e0139474.
Gripshover BM, Ribaudo H, Santana J, et al. "Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)." Antivir. Ther. (Lond.). 2006;11(5):619-23.
Eshleman SH, Hudelson SE, Redd AD, et al. "Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial." J. Infect. Dis.. 2011;204(12):1918-26.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
Taiwo B, Gallien S, Aga E, et al. "Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy." J. Infect. Dis.. 2011;204(4):515-20.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
Zheng Y, Hughes MD, Lockman S, et al. "Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens." Clin. Infect. Dis.. 2014;59(6):888-96.
George E, Noël F, Bois G, et al. "Antiretroviral therapy for HIV-1-infected children in Haiti." J. Infect. Dis.. 2007;195(10):1411-8.
Volberding P, Demeter L, Bosch RJ, et al. "Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment." AIDS. 2009;23(15):1987-95.
Richman DD. "Antiviral drug resistance." Antiviral Res.. 2006;71(2-3):117-21.
Hosoya N, Su Z, Wilkin T, et al. "Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions." J. Clin. Microbiol.. 2009;47(8):2604-6.
Yiannoutsos CT, Nakas CT, Navia BA. "Assessing multiple-group diagnostic problems with multi-dimensional receiver operating characteristic surfaces: application to proton MR Spectroscopy (MRS) in HIV-related neurological injury." Neuroimage. 2008;40(1):248-55.
Mollan KR, Smurzynski M, Eron JJ, et al. "Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data." Ann. Intern. Med.. 2014;161(1):1-10.
Cu-Uvin S, Snyder B, Harwell JI, et al. "Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months." J. Acquir. Immune Defic. Syndr.. 2006;42(5):584-7.
Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. "Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy." Diabetes Care. 2010;33(10):2244-9.
Demeter LM, Degruttola V, Lustgarten S, et al. "Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience." HIV Clin Trials. 2008;9(1):11-25.

Pages